<SEC-DOCUMENT>0001193125-17-339045.txt : 20171109
<SEC-HEADER>0001193125-17-339045.hdr.sgml : 20171109
<ACCEPTANCE-DATETIME>20171109172706
ACCESSION NUMBER:		0001193125-17-339045
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171109
FILED AS OF DATE:		20171109
DATE AS OF CHANGE:		20171109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prima BioMed Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		171192087

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d486728d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated November 9, 2017 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>PRIMA BIOMED
LTD </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s Name) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;&#9746; Form
40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)
(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)
(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;&#9746;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman"><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">NEW EFTILAGIMOD ALPHA (LAG-3lg OR IMP321) DATA FOR PRESENTATION AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2017 ANNUAL
MEETING</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: November 9, 2017 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PRIMA BIOMED LTD</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U></U>Title:&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d486728dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g486728001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9&nbsp;November 2017 </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEW EFTILAGIMOD ALPHA
(LAG-3Ig or IMP321) DATA FOR PRESENTATION AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2017 ANNUAL MEETING </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA&#151;Prima BioMed
Ltd (ASX: PRR; NASDAQ: PBMD) (&#147;Prima&#148;) is pleased to announce the presentation of new data from its TACTI-mel Phase I clinical trial in Australia investigating the use of eftilagimod alpha (LAG-3Ig or IMP321), the Company&#146;s lead
product candidate, in combination with pembrolizumab (KEYTRUDA) in unresectable or metastatic melanoma patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The data will be presented in the poster
titled &#147;Pushing the accelerator and releasing the brake: testing the soluble LAG-3 protein (IMP321), an antigen presenting cell activator, together with pembrolizumab in unresectable or metastatic melanoma&#148; (Poster Number P259) for the
first time at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting, to be held on November&nbsp;10-12, 2017 at the Gaylord National Hotel&nbsp;&amp; Convention Center in National Harbor, Maryland. Eftilagimod alpha, which is a soluble
LAG-3Ig fusion protein, is an APC activator boosting T cell responses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The data to be presented at the SITC meeting is very encouraging and
demonstrates that anti-tumor activity was observed in patients following the administration of eftilagimod alpha in combination with pembrolizumab. Furthermore, it is important to note that prior to coming into this study, these patients were
treated with pembrolizumab monotherapy and did not achieve a meaningful therapeutic benefit from this treatment,&#148; stated Dr.&nbsp;Fr&eacute;d&eacute;ric Triebel, Prima&#146;s Chief Scientific Officer and Medical Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patients eligible to participate in the TACTI-mel Phase 1 clinical trial are those that have either had a suboptimal response or had disease progression
with KEYTRUDA monotherapy as a first-line of treatment. 12 patients from the first two cohorts of the trial were treated with 1 and 6mg doses of eftilagimod alpha respectively. The third cohort of patients, being treated with 30 mg doses, is
ongoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Fr&eacute;d&eacute;ric Triebel further commented, &#147;The data also supports the hypothesis that there is a therapeutic synergy when
administering an APC activator, which enhances anti-tumor T cell production, in combination with a checkpoint inhibitor, which releases the brake on the T cells.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The presentation at the SITC conference includes the following results: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Combination of eftilagimod alpha (1 and 6 mg) and pembrolizumab in advanced metastatic melanoma patients is safe and well tolerated; </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Anti-tumor activity (tumor reduction) was observed in 7/12 patients (58 %) in this study; prior to the study all of these patients either had a suboptimal response or had disease progression when treated with the
pembrolizumab monotherapy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Data presented supports the hypothesis that combining an APC activator (IMP321) with a checkpoint inhibitor (pembrolizumab) results in a therapeutic synergy and a potential clinical benefit over a checkpoint inhibitor
monotherapy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Data presented supports further investigation of IMP321 in combination with PD-1/ PD-L1 checkpoint inhibitors in different tumor types. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marc Voigt, Prima&#146;s Chief Executive Officer, added, &#147;We believe the positive data, taken together with the excellent safety profile of eftilagimod
alpha and data from our ongoing clinical trial in metastatic breast cancer, further validate the therapeutic utility of modulating the LAG-3 immune control mechanism. We are very pleased with the clinical progress of eftilagimod alpha and look
forward to presenting additional data from the TACTI-mel clinical trial and exploring the potential therapeutic benefit of combining it with other checkpoint inhibitors in other solid tumors.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of this SITC poster presentation is available on Prima&#146;s website in the Presentations section of the Investors tab at
<U>http://primabiomed.com.au/investor/presentations.php</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prima BioMed </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is a globally active biotechnology company that is a leader in the development of immunotherapeutic products. Prima BioMed is dedicated to
leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima&#146;s
current lead product is eftilagimod alpha (LAG-3Ig or IMP321), based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response. Eftilagimod alpha is the International Nonproprietary Name (INN) for
IMP321. Each INN is a unique name that is globally recognized to identify pharmaceutical substances or active pharmaceutical ingredients, and is regulated by the World Health Organisation (WHO). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eftilagimod alpha, which is a soluble LAG-3Ig fusion protein, is an APC activator boosting T cell responses. Eftilagimod alpha is currently in a Phase II
clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier <U>NCT 02614833</U>) and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier
<U>NCT 02676869</U>). A number of additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by Prima&#146;s pharmaceutical partners. Prima is also developing an agonist of LAG-3
(IMP761) for autoimmune disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is listed on the Australian Securities Exchange (PRR) and on the NASDAQ (PBMD) in the US. For further
information please visit <U>www.primabiomed.com.au</U>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information please contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay Campbell, Vice President of Business
Development and Investor Relations, Prima Biomed </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (917)&nbsp;860-9404; <U>jay.campbell@primabiomed.com.au</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew Beck, The Trout Group LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (646)&nbsp;378-2933;
<U>mbeck@troutgroup.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew Gregorowski, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 2 8234 0105;
<U>mgregorowski@citadelmagnus.com</U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g486728001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g486728001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ >P++ P$1  (1 0,1 ?_$ +(  0 " @,!
M       "! $#!0<(!@$! 0$! 0$! 0            $" P0&!P40  $# P$$
M!@4'" 4*!P$   $  @,1! 4&(3$2!T%1<;$R$V'!T2((@9%B<B,S%*%"4H*2
MDU46LD-C@T6BTE-S)#1$%247PK-TE#4V&#@1 0 "  ,%!P0" @,!       !
M A$#!#%!410%(9$20E(3!F&!H15Q,O 6L=$B8O_:  P# 0 "$0,1 #\ ]4J
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M %CF686U?<V&3EJ+>&\8&-D<-O"Q[2X<7H*#D-3\Z-/:=UYC]%WEI=29')&
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M&ET[ST-C KZ4'/:$TI!I/2F-T];R&:/'PB,S.V%[R2Y[J>EQ*@Y] 0%00$!
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MD-/\KB7.='67JIUW41O<;-R-PQ^XR%PSZX8[V+E.@J]5?D>;OAQMSR,O0?\
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MNH]$MC=<Z4=_B40[:CU*\S0_6Y_HEL&LM*G=DX/E<GOY?$_79_HLD-7Z6/\
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M7((U*J,(VB4&":H,(!W)#3"T@BP**@>E08*L J" I(B[>H,(/9*^D?D@@("
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M" @(" @(" @(" @(" @(" @(" @(" @(%$! 0*(%$&" @<(1,&.$=2N,KB4
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MJ_\ V T[_$;O?7='NZMRS^MIQ;_V?-]-?R[57]%\V(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
@@(" @(" @(" @(" @(" @(" @(" @(" @(" @("#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
